Pharma BD Deal Intelligence
Gilead paid $55M upfront plus $54M in research funding, with up to $2B in milestones, to option Goldfinch Bio's kidney disease pipeline—a bet on undisclosed early-stage candidates that never advanced to a milestone payout worth reporting.
Gilead and Goldfinch Bio enter $2 billion-plus partnership to develop kidney disease drugs leveraging Goldfinch Kidney Genome Atlas technology platform.
Startup Goldfinch Bio signs $109 million upfront deal with Gilead to develop treatments for kidney disease, with total potential value exceeding $2 billion.
Karuna Therapeutics announces exclusive global license to Goldfinch Bio's TRPC4/5 candidates (incl GFB-887) from the Goldfinch assignment estate (Feb 2,…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Gilead partnered with Goldfinch Bio to develop kidney disease therapies, paying $55M upfront plus $54M in research funding with up to $2B in milestones.
Acute Kidney Injury (AKI) has no FDA-approved disease-modifying pharmacotherapy. Standard of care is supportive (fluid management, dialysis when needed). Failed Phase 3 programs: teprasiran (QPI-1002, Quark; discontinued after AKI-POST and AKI-PRE trials); ANG-3777 (Angion; failed Phase 3 2021). Other investigational: ciclosporin (CicloMulsion), levosimendan, intravenous human albumin. Gilead/Goldfinch's acquisition was primarily for Goldfinch's kidney disease platform (focal segmental glomerulosclerosis, diabetic kidney disease) rather than AKI specifically. Competitive field is effectively empty for AKI-specific therapeutics.
Gilead paid $55M upfront + $54M research funding for kidney disease therapy development.
GFB-887 Phase 2 showed mixed results. Goldfinch failed to secure financing and closed. Pipeline sold to Karuna.
Goldfinch Bio shut down after clinical setbacks and funding failure. Gilead lost $109M in payments.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Goldfinch Bio Inc. (this deal) | 2019 | $240M | 26 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2019 deals · Gilead Sciences Inc. deals · Nephrology deals